Hamandi Khalid, Sander Josemir W
Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK.
Seizure. 2006 Mar;15(2):73-8. doi: 10.1016/j.seizure.2005.11.005. Epub 2006 Jan 18.
Pregabalin is a recently licensed and marketed antiepileptic drug for use as adjunctive treatment of partial epilepsy. It acts at presynaptic calcium channels, modulating neurotransmitter release in the CNS, properties it shares with gabapentin. Its clinical development over the past decade has included its use in the treatment of neuropathic pain, and generalized anxiety disorder, in addition to epilepsy. Three multi-centre randomised, double-blind, placebo-controlled trials enrolling patients with refractory partial epilepsy have demonstrated an antiepileptic effect of pregabalin against placebo, as adjunctive therapy, with 31-51% of patients showing a 50% reduction in seizure frequency. Adverse effects were dose related, the commonest being somnolence, dizziness, and ataxia. Weight gain was seen in 14% of patients on the highest dose of 600 mg/day. Around 9000 people have been exposed to pregabalin in its development for all indications. No idiosyncratic reactions have been described to date. Pregabalin may be a useful addition in the treatment of refractory partial epilepsy. As with all new AEDs long-term follow up and post marketing surveillance is required.
普瑞巴林是一种最近获得许可并上市的抗癫痫药物，用作部分性癫痫的辅助治疗。它作用于突触前钙通道，调节中枢神经系统中的神经递质释放，这一特性与加巴喷丁相同。在过去十年中，其临床开发包括用于治疗神经性疼痛和广泛性焦虑症，以及癫痫。三项纳入难治性部分性癫痫患者的多中心随机、双盲、安慰剂对照试验表明，普瑞巴林作为辅助治疗，对安慰剂具有抗癫痫作用，31%至51%的患者癫痫发作频率降低了50%。不良反应与剂量相关，最常见的是嗜睡、头晕和共济失调。在最高剂量每天600毫克的患者中，14%出现体重增加。在其针对所有适应症的研发过程中，约9000人接触过普瑞巴林。迄今为止，尚未发现特异反应。普瑞巴林可能是难治性部分性癫痫治疗中的一种有用药物。与所有新型抗癫痫药物一样，需要进行长期随访和上市后监测。
